title: Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.
abstract: The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.
authors.affiliation: Centre for Lysosomal Storage Disorders, Children's Hospital, Mainz, Germany. mr380t@nih.gov
authors.forename: M
authors.initials: M
authors.lastname: Ries
authors.forename: E
authors.initials: E
authors.lastname: Mengel
authors.forename: G
authors.initials: G
authors.lastname: Kutschke
authors.forename: K S
authors.initials: KS
authors.lastname: Kim
authors.forename: F
authors.initials: F
authors.lastname: Birklein
authors.forename: F
authors.initials: F
authors.lastname: Krummenauer
authors.forename: M
authors.initials: M
authors.lastname: Beck
mesh_terms: D000085:Acetates / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids; D000795:Fabry Disease / Q000150:complications*; D000077206:Gabapentin; D006801:Humans; D008297:Male; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D010147:Pain Measurement; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid
chemical_list: D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin